发明名称 Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor GW4869 for degenerative neurological disorders
摘要 Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. It was discovered that antisense oligonucleotide against neutral sphingomyelinase and GW4869, a chemical inhibitor of neutral sphingomyelinase, inhibit activation of glial cells and protect neurons in AD cell culture and animal models. These results suggest the following new treatment options for AD patients: Antisense oligonucleotide against neutral sphingomyelinase and GW4869.
申请公布号 US9006205(B2) 申请公布日期 2015.04.14
申请号 US201214118725 申请日期 2012.05.21
申请人 Rush University Medical Center 发明人 Pahan Kalipada
分类号 A61K48/00;C07H21/02;C07H21/04;A61K38/00;A61P25/28;A61K31/4178;A61K31/7088;C12N15/113 主分类号 A61K48/00
代理机构 Brinks Gilson & Lione 代理人 Brinks Gilson & Lione
主权项 1. A method of treating a neurodegenerative disorder in a mammal in need thereof, the method comprising: administering a composition comprising GW4869 to the mammal to treat the neurodegenerative disorder.
地址 Chicago IL US
您可能感兴趣的专利